Skip to main content
Advertisement
Advertisement

AKBA

AKBA logo

Akebia Therapeutics, Inc.

0.93
USD
Sponsored
-0.05
-4.84%
Sep 23, 15:59 UTC -4
Closed
exchange

After-Market

0.94

0.00
+0.26%

AKBA Earnings Reports

Positive Surprise Ratio

AKBA beat 19 of 43 last estimates.

44%

Next Report

Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$47.88M
/
-$0.03
Implied change from Q2 26 (Revenue/ EPS)
-2.54%
/
--
Implied change from Q3 25 (Revenue/ EPS)
-18.53%
/
--

Akebia Therapeutics, Inc. earnings per share and revenue

On Aug 05, 2026, AKBA reported earnings of -0.03 USD per share (EPS) for Q2 26, beating the estimate of -0.04 USD, resulting in a 33.18% surprise. Revenue reached 49.13 million, compared to an expected 49.84 million, with a -1.43% difference. The market reacted with a -26.02% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.03 USD, with revenue projected to reach 47.88 million USD, implying an increase of 0.00% EPS, and decrease of -2.54% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Akebia Therapeutics, Inc. reported EPS of -$0.03, beating estimates by 33.18%, and revenue of $49.13M, -1.43% below expectations.
The stock price moved down -26.02%, changed from $1.29 before the earnings release to $0.95 the day after.
The next earning report is scheduled for Nov 09, 2026.
Based on 6 analysts, Akebia Therapeutics, Inc. is expected to report EPS of -$0.03 and revenue of $47.88M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement